Cytochalasin J |
| Catalog No.GC10870 |
alters mitotic spindle microtubule organization and kinetochore structure
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 53760-20-6
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Cytochalasin J can alter mitotic spindle microtubule organization and kinetochore structure.
The cytochalasins are cell-permeable fungal metabolites inhibiting actin polymerization, which can alter diverse processes including cell movement, growth, phagocytosis, degranulation, and secretion.
In vitro: Cytochalasin J was identified as a deacetylated analog of cytochalasin H that weakly inhibited actin assembly but significantly altered mitotic spindle microtubule organization and kinetochore structure [1]. In a previous study, cytochalasin J treatment of prometaphase cells reduced the number of kMTs and the size and organization of the kinetochore lamina. Moreover, in approximately 30% of cells treated with cytochalasin J, the failure of a small number of chromosomes to attach to spindle fibers could be documented. These chromosomes showed a significant change in the organization of the kinetochore laminae. Light microscopic analyses of cells treated with cytochalasin J revealed loss of chromosome congression, with chromsomes usually located at the periphery of the spindle. Cells treated with 10 microg/ml cytochalasin J for 10 min and released into tissue culture medium showed a resumption of chromosome motion within a few minutes, both during congression and anaphase [2].
In vivo: Up to now, there is no animal in vivo data reported.
Clinical trial: So far, no clinical study has been conducted.
References:
[1] Walling, E. A.,Krafft, G.A. and Ware, B.R. Actin assembly activity of cytochalasins and cytochalasin analogs assayed using fluorescence photobleaching recovery. Archives of Biochemistry and Biophysics 264(1), 321-332 (1988).
[2] Wrench, G. A. and Snyder, J.A. Cytochalasin J treatment significantly alters mitotic spindle microtubule organization and kinetochore structure in PtK1 cells. Cell Motility and the Cytoskeleton 36(2), 112-124 (1997).
| Cas No. | 53760-20-6 | SDF | |
| Chemical Name | 2,3,3a,4,5,6,6a,9,10,11,12,15-dodecahydro-6,12,15-trihydroxy-4,10,12-trimethyl-5-methylene-3-(phenylmethyl)-1H-cycloundec[d]isoindol-1-one | ||
| Canonical SMILES | O=C1N[C@@H](CC2=CC=CC=C2)[C@]([C@]31[C@H](O)/C=C/[C@](C)(O)C[C@@H](C)C/C=C/[C@@]3([H])[C@@H]4O)([H])[C@H](C)C4=C | ||
| Formula | C28H37NO4 | M.Wt | 451.6 |
| Solubility | Soluble in ethanol;Soluble in methanol;Soluble in DMSO;Soluble in dimethyl formamide | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.2143 mL | 11.0717 mL | 22.1435 mL |
| 5 mM | 0.4429 mL | 2.2143 mL | 4.4287 mL |
| 10 mM | 0.2214 mL | 1.1072 mL | 2.2143 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 23 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *